Projected Income Statement: Bio-Techne Corporation

Forecast Balance Sheet: Bio-Techne Corporation

Fiscal Period: June 2020 2021 2022 2023 2024 2025 2026 2027
Net Debt 1 85.9 110 8.88 146 166 -58 -384 -749
Change - 28.06% -91.93% 1,544.14% 13.7% -134.91% -762.07% -295.05%
Announcement Date 8/4/20 8/5/21 8/4/22 8/8/23 8/7/24 - - -
1USD in Million
Estimates

Cash Flow Forecast: Bio-Techne Corporation

Fiscal Period: June 2020 2021 2022 2023 2024 2025 2026 2027
CAPEX 1 51.74 44.3 44.91 38.24 62.88 45 50.24 54.36
Change - -14.38% 1.37% -14.84% 64.41% -28.43% 11.63% 8.19%
Free Cash Flow (FCF) 1 153.2 307.9 280.4 216.1 236.1 294.9 367.8 721.4
Change - 100.89% -8.93% -22.9% 9.23% 24.88% 24.73% 96.17%
Announcement Date 8/4/20 8/5/21 8/4/22 8/8/23 8/7/24 - - -
1USD in Million
Estimates

Forecast Financial Ratios: Bio-Techne Corporation

Fiscal Period: June 2020 2021 2022 2023 2024 2025 2026 2027

Profitability

        
EBITDA Margin (%) 36.3% 41.43% 40.64% 38.8% 35.46% 34.66% 36.33% 36.2%
EBIT Margin (%) 33.34% 38.9% 38.11% 36.09% 31.94% 31.63% 33.42% 33.75%
EBT Margin (%) 37.43% 15.92% 27.26% 29.79% 16.02% 18.13% 24% 25.6%
Net margin (%) 31.04% 15.08% 24.61% 25.1% 14.5% 15.63% 19.3% 21.43%
FCF margin (%) 20.75% 33.07% 25.36% 19.02% 20.37% 23.95% 27.39% 48.41%
FCF / Net Income (%) 66.83% 219.26% 103.06% 75.77% 140.45% 153.19% 141.93% 225.86%

Profitability

        
ROA 9.17% 6.55% 11.94% 13.03% 6.29% 10% 10.84% 10.38%
ROE 14.08% 9.51% 16.63% 17.53% 14.11% 14.29% 14.56% 14.48%

Financial Health

        
Leverage (Debt/EBITDA) 0.32x 0.28x 0.02x 0.33x 0.4x - - -
Debt / Free cash flow 0.56x 0.36x 0.03x 0.67x 0.7x - - -

Capital Intensity

        
CAPEX / Current Assets (%) 7% 4.76% 4.06% 3.36% 5.42% 3.66% 3.74% 3.65%
CAPEX / EBITDA (%) 19.3% 11.49% 9.99% 8.67% 15.3% 10.54% 10.3% 10.08%
CAPEX / FCF (%) 33.76% 14.39% 16.02% 17.69% 26.63% 15.26% 13.66% 7.53%

Items per share

        
Cash flow per share 1 1.302 2.174 1.982 1.572 1.86 2.141 2.584 2.733
Change - 66.98% -8.85% -20.7% 18.32% 15.13% 20.69% 5.77%
Dividend per Share 1 0.32 0.32 0.32 0.32 0.32 0.32 0.3333 0.32
Change - 0% 0% 0% 0% 0% 4.17% -4%
Book Value Per Share 1 8.764 10.03 10.36 12.14 13.08 14.03 16.03 19.08
Change - 14.45% 3.34% 17.18% 7.67% 7.31% 14.27% 19.01%
EPS 1 1.455 0.8675 1.658 1.76 1.05 1.186 1.578 1.91
Change - -40.38% 91.07% 6.18% -40.34% 12.92% 33.11% 21.01%
Nbr of stocks (in thousands) 152,892 155,567 156,934 157,437 157,585 158,892 158,892 158,892
Announcement Date 8/4/20 8/5/21 8/4/22 8/8/23 8/7/24 - - -
1USD
Estimates
2025 *2026 *
P/E ratio 63.5x 47.7x
PBR 5.36x 4.69x
EV / Sales 9.66x 8.62x
Yield 0.43% 0.44%
More valuation ratios * Estimated data

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
75.01USD
Average target price
86.80USD
Spread / Average Target
+15.72%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. TECH Stock
  4. Financials Bio-Techne Corporation